55 results
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals, Inc.
1 Aug 24
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
4:10pm
, Longboard’s cash, cash equivalents and short-term investments were approximately $304.9 million.
Operating Results
Research and development expenses … in other miscellaneous research and development related expenses.
General and administrative expenses were $5.2 million for the three months ended
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals, Inc.
1 Jul 24
Regulation FD Disclosure
9:15am
; Longboard’s product candidates are in a lengthy research and development process, the timing, manner and outcome of research, development and regulatory review … is uncertain, and Longboard’s product candidates, including bexicaserin and LP659, may not advance in research or development or be approved
8-K
LBPH
Longboard Pharmaceuticals, Inc.
1 Jul 24
Regulation FD Disclosure
9:15am
the designation is no longer supported by subsequent data; Longboard's product candidates are in a lengthy research and development process, the timing … , manner and outcome of research, development and regulatory review is uncertain, and Longboard's product candidates, including bexicaserin and LP659
8-K
LBPH
Longboard Pharmaceuticals, Inc.
10 Jun 24
Regulation FD Disclosure
9:05am
of a lengthy research and development process, the timing, manner and outcome of research, development and regulatory review is uncertain, and Longboard's … product candidates may not advance in research or development or be approved for marketing; enrolling participants in Longboard's ongoing
8-K
EX-99.1
tmaba rcfzyycy
10 Jun 24
Regulation FD Disclosure
9:05am
8-K
EX-99.1
ly8 eqg50p
2 May 24
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
4:10pm
PRE 14A
jf8fz61f8br 0lg98r
28 Mar 24
Preliminary proxy
4:36pm
S-3ASR
hxjg3qasm2p vq3
12 Mar 24
Automatic shelf registration
4:45pm
8-K
EX-99.1
2820aggrtq
12 Mar 24
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
4:10pm
424B5
uy7dy
4 Jan 24
Prospectus supplement for primary offering
4:48pm
424B5
hafoir5be2o nms1
2 Jan 24
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
t4qx54dec3rfy5wrl
2 Jan 24
Regulation FD Disclosure
9:44am
8-K
rwg4l5i129f2qqpm wt
2 Jan 24
Regulation FD Disclosure
9:44am
8-K
EX-99.1
xye0rrlc1b0
2 Nov 23
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
5iz215f
23 Aug 23
Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study
8:46am